Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eric Bannasch, Cadian Capital Add to Position in Green Plains Renewable Energy

Cadian Capital, managed by Eric Bannasch, is betting big on Green Plains Renewable Energy Inc. (NASDAQ:GPRE). The fund has revealed, in a recent filing with the Securities and Exchange Commission, an addition to their holding of Green Plains stock. Cadian has increased the number of shares owned to 3.8 million, representing 12.55% of the company’s common stock. Prior to that the fund held a little over 1.5 million shares.

Green Plains Renewable Energy Inc. (NASDAQ:GPRE)

Another fund that is particularly bullish on this stock is Aqr Capital Management, run by Cliff Asness. In their most recent 13F filing, the fund reported ownership of 600K shares valued at $9.6 million. During the third quarter of 2013,  Asness increased the investment in Green Plains Renewable Energy by 68%. In the mean timeKen Griffin‘s Citadel Investment Group has been reducing their position in the company by 57%. In their latest 13F filing, Citadel revealed ownership of 137K shares, reportedly worth $2.2 million.

Green Plains Renewable Energy engages in the production and distribution of ethanol in the United States. Company shares have been in an uptrend in 2013, rising 90% to a current price of $15.28. Shares have a trailing Price to Earnings (P/E) ratio of 10.02 and a beta of 1.33. Earlier this year the company instated a quarterly dividend of $0.04 per share. For the third quarter of 2013, Green Plains reported revenues of $757 million and earnings per diluted share (EPS) of $0.28. Market participants expect the company to increase their revenues to $795 million and earnings to $0.39 per share in the current quarter. The stock price is expected to further rise, with a mean target of $19.58.

Disclosure: none

Recommended reading:

Barry Rosenstein, Jana Partners Cut Their Stake in Oil States International

Starboard Value, Elliott Associates Sell Shares of Emulex Corporation

Jeffrey Jacobs Change His Mind Regarding MTR Gaming Group – Eldorado Resorts Merger

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!